Tildrakizumab use for recalcitrant pityriasis rubra pilaris-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Tildrakizumab use for recalcitrant pityriasis rubra pilaris

Published:2024-05-30 Issue:5 Volume:65 Page:476-479
ISSN:0004-8380
Container-title:Australasian Journal of Dermatology
language:en
Short-container-title:Aust J Dermatology

Author:

Holmes Zachary¹^ORCID,Goh Michelle S.¹,Foley Peter¹²³^ORCID,Daniel Benjamin S.¹⁴^ORCID

Affiliation:

1. Department of Dermatology St Vincent's Hospital Melbourne Fitzroy Victoria Australia

2. Skin Health Institute Carlton Victoria Australia

3. The University of Melbourne Melbourne Victoria Australia

4. Faculty of Medicine University of New South Wales Sydney New South Wales Australia

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajd.14307

Reference10 articles.

1. Pityriasis rubra pilaris treatment options: A retrospective case series from a tertiary hospital

2. Biologics for pityriasis rubra pilaris treatment: A review of the literature

3. Biologic treatment options for pityriasis rubra pilaris: An evidence-based systematic review

4. Successful treatment of pityriasis rubra pilaris with tildrakizumab

5. Refractory Type I pityriasis rubra pilaris treated with tildrakizumab

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging Role of Biologic Drugs Targeting IL-17 and IL-23: Pityriasis Rubra Pilaris;Life;2024-07-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3